Featured Research

from universities, journals, and other organizations

Drug shows promise in prostate cancer spread to bone: Tumors were reduced on bone scans, bone pain decreased after patients received cabozantinib

Date:
December 4, 2012
Source:
University of Michigan Health System
Summary:
A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a new study.

A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.

About two-thirds of patients treated with cabozantinib had improvements on their bone scans, with 12 percent seeing complete resolution of uptake on bone scan. Bone scans assess the degree to which cancer is in the bone; improvements on these scans suggest a response to the drug.

"The effects of cabozantinib on bone scans are unprecedented in the treatment of prostate cancer," says lead study author David C. Smith, M.D., professor of internal medicine and urology at the University of Michigan Medical School.

Cabozantinib is designed to target two important pathways linked to the growth and spread of prostate cancer. The drug had the most effect on tumors that had spread to the bone, which is the major site where prostate cancer spreads. These tumors are typically very challenging to treat once they become resistant to hormone-based therapies.

In addition to the improvements on bone scans, 67 percent of patients with bone pain reported an improvement in pain control and 56 percent decreased or eliminated narcotic painkillers after treatment with cabozantinib. Results of the study appear in the Journal of Clinical Oncology.

The trial enrolled 171 men with castration-resistant prostate cancer, meaning their tumors no longer responded to hormone-based therapies. The study began as a randomized trial in which all patients received cabozantinib for 12 weeks, after which patients were randomized to receive continued cabozantinib or placebo. The randomization was stopped early because of the dramatic effects on bone scan, and because patients receiving placebo saw their cancer progress much more quickly than those that remained on drug.

Among the 31 patients who were randomized, cancer progressed after a median 23.9 weeks for patients taking cabozantinib, compared with 5.9 weeks for patients on placebo.

"Discontinuing randomization is not common. Stabilization of disease in advanced prostate cancer is rarely due to the natural history of the disease and is in this case due to drug effect," Smith says.

"While these initial results are promising, we are still uncertain how cabozantinib will impact the gold standard of survival," he adds.

Phase III studies have begun at some institutions, and U-M researchers are conducting a phase II study to better understand the effect cabozantinib has on bone. This drug is not offered routinely in clinical care at this time. For information about prostate cancer treatment options or clinical trials currently open at the U-M Comprehensive Cancer Center, call the Cancer AnswerLine at 800-865-1125.

Prostate cancer statistics: 241,740 Americans will be diagnosed with prostate cancer this year and 28,170 will die from the disease, according to the American Cancer Society


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. D. C. Smith, M. R. Smith, C. Sweeney, A. A. Elfiky, C. Logothetis, P. G. Corn, N. J. Vogelzang, E. J. Small, A. L. Harzstark, M. S. Gordon, U. N. Vaishampayan, N. B. Haas, A. I. Spira, P. N. Lara, C.-C. Lin, S. Srinivas, A. Sella, P. Schoffski, C. Scheffold, A. L. Weitzman, M. Hussain. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. Journal of Clinical Oncology, 2012; DOI: 10.1200/JCO.2012.45.0494

Cite This Page:

University of Michigan Health System. "Drug shows promise in prostate cancer spread to bone: Tumors were reduced on bone scans, bone pain decreased after patients received cabozantinib." ScienceDaily. ScienceDaily, 4 December 2012. <www.sciencedaily.com/releases/2012/12/121204145657.htm>.
University of Michigan Health System. (2012, December 4). Drug shows promise in prostate cancer spread to bone: Tumors were reduced on bone scans, bone pain decreased after patients received cabozantinib. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2012/12/121204145657.htm
University of Michigan Health System. "Drug shows promise in prostate cancer spread to bone: Tumors were reduced on bone scans, bone pain decreased after patients received cabozantinib." ScienceDaily. www.sciencedaily.com/releases/2012/12/121204145657.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins